Indaptus Therapeutics is trading at $2.87 (+10%) in pre-market, staging a recovery after shares fell approximately 5–7% during Friday's profit-taking session.
- The move follows several days of sharp gains earlier last week, with the current bounce occurring on no fresh company-specific headlines, earnings, or analyst updates.
- Analysts attribute the price action to a rebound in a thinly traded biotech name amid a broadly stronger risk-on market tone.